Multiple endocrine neoplasia type 2: achievements and current challenges

Area of Science:

• Endocrinology
• Medical Genetics
• Oncology

Background:

• Medical technology, particularly sensitive hormonal assays, drives progress in clinical care.
• The concept of multiple endocrine neoplasia type 2 (MEN2), involving medullary thyroid cancer, pheochromocytoma, and primary hyperparathyroidism, emerged in the 1960s.
• Advances enable integrated DNA-based and biochemical screening for MEN2 risk.

Purpose of the Study:

• To review key achievements in MEN2 screening.
• To highlight current challenges in implementing integrated screening protocols.
• To discuss the interpretation of genetic variants in MEN2.

Main Methods:

• Review of medical technology advancements and screening strategies for MEN2.
• Analysis of challenges in biochemical assays for infants and children.
• Discussion of genetic testing and variant characterization for MEN2 predisposition.

Main Results:

• Joint biochemical and DNA-based screening represents a significant achievement for individuals at risk of MEN2.
• Challenges include undefined calcitonin assay limits in young children and difficulties in obtaining family history in mobile societies.
• DNA testing can confirm genetic predisposition before clinical or biochemical evidence, but interpreting novel gene variants requires functional characterization.

Conclusions:

• Integrated DNA-based and biochemical screening is crucial for early MEN2 detection.
• Addressing challenges in pediatric assays and genetic variant interpretation is essential for effective MEN2 management.
• Molecular genetic progress in MEN2 necessitates careful evaluation of gene sequence variants.